-
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024
Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments…
-
ESMO Asia China Voice | Dr. Zhi Peng Interprets DESTINY-Gastric06: ADC Therapy Unveils a New Era for Advanced HER2-Positive Gastric Cancer Treatment
________________________________________ Oncology Frontier: You presented the findings of the DESTINY-Gastric06 study at the congress. Could you introduce the background of the study and its key results? Dr. Zhi Peng: The…
-
ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer
Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo…
-
ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference,…
-
Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma
In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian…
-
Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024
In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked…
-
Dr. Charles E. Geyer, Jr.: Atezolizumab in TNBC – Insights from the NSABP B-59/GBG-96-GeparDouze Trial
Dr. Charles Geyer, Jr.. presented findings from the NSABP B-59/GBG-96-GeparDouze phase III trial, evaluating the addition of atezolizumab to neoadjuvant chemotherapy, followed by adjuvant atezolizumab, in stage II-III triple-negative breast cancer (TNBC).
-
EORTC-1203 GITC “INNOVATION”: Evaluating HER2-Targeted Perioperative Therapy in Stomach Cancer
At ASCO GI 2025, Anna Dorothea Wagner and colleagues presented the EORTC-1203 “INNOVATION” trial, investigating trastuzumab (T) ± pertuzumab (P) with perioperative chemotherapy (CT) in HER2+ gastric and esophagogastric junction…
Connecting Medical Expertise through Media